Paclitaxel = Taxol
Docetaxel = Taxotere
Benefits of Weekly Taxol in TNBC
Sequential doxorubicin plus cyclophosphamide followed by weekly paclitaxel is a reasonable adjuvant treatment option for triple-negative breast cancer, according to 12-year follow-up of the Eastern Cooperative Oncology Group's E1199 phase III trial evaluating optimal taxane type and scheduling in operable breast cancer. . .
. . .“[The data] support current practice for the use of a dose-dense schedule -- weekly Taxol in this study -- for improving outcomes, particularly for patients with triple-negative breast cancer, and the findings should be considered when selecting adjuvant therapy in this setting,”